COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Virios Therapeutics Inc
Study evaluating IMC-2 in Long-COVID treatment was initiated-reported on Aug.15, 2022.
Ascletis Pharma Inc.
China National Medical Products Administration accepted the Investigational New Drug (IND) application of ASC10 for the treatment of Covid-19- reported on Aug 03, 2022.

The FDA gave clearance to conduct Phase Ib study of ASC10 in mild-to-moderate COVID-19 patients-reported on Aug 03, 2022.

IND application of ASC10 for the treatment of Covid-19 has been filed with the FDA- reported on Jul 05, 2022.
Sorrento Therapeutics, Inc.
STI-1558 to treat Covid-19
Multiple ascending dose (MAD) Phase 1 study of STI-1558 was initiated following successful completion of single ascending dose (SAD) study- reported on Aug 03, 2022

The FDA has cleared the Investigational New Drug application for a Phase 1 pharmacokinetic study of STI-1558 in patients with impaired renal and hepatic function- reported on July 19, 2022.
SyneuRx International
Results from Phase 2 study showed that Pentarlandir can reduce the inflammation caused by COVID-19 and improve overall health- reported on July 31, 2022.

On Nov.19, 2021, the company announced that pentarlandir has shown significant anti-viral properties with minimal observed side effects in the phase II study.
Phase 3 study to be launched in the coming months.
AIM ImmunoTech Inc.
Preliminary data from the pilot study showed that patients with long COVID had statistically significant improvements in chronic fatigue after treatment with Ampligen- reported on July 28, 2022.

After at least 12 weeks of Ampligen treatment, four patients with new onset Myalgic encephalomyelitis/chronic fatigue syndrome, following acute COVID-19, experienced a reduction in fatigue- reported on May 18, 2022.
An IND application to be submitted with the FDA for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions
InflaRx N.V.
IFX-1 (vilobelimab)
Topline results from the Phase III part of Phase II/III PANAMO study of Vilobelimab in mechanically ventilated COVID-19 patients showed a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo, but did not show statistical significance on the pre-specified primary endpoint- reported on March 31, 2022.
Emergency Use Authorization (EUA) application for Vilobelimab to be submitted in Q3 2022
Brii Biosciences Limited
BRII-196 and BRII-198
New live virus data showed that the BRII-196 and BRII-198 (amubarvimab/ romlusevimab) combination, retains neutralizing activity against the Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2 subvariants- reported on Jul 26, 2022.
Vaxart, Inc.
Oral tablet COVID-19 vaccine
Additional data from the Phase 1 study showed that tablet COVID-19 vaccine induced long-lasting mucosal IgA antibodies against SARS-CoV-2, and all tested coronaviruses- reported on July 20, 2022.

Phase 2 study of Oral Tablet COVID-19 Vaccine was initiated on October 26, 2021.
Data from the dose selection portion of the two part dose-ranging and preliminary efficacy Phase II trials of oral tablet COVID-19 vaccine candidate are expected in the third quarter of 2022.

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Home improvement retailer Lowe's Cos., Inc. reported Wednesday an increase in earnings per share for the second quarter that also topped analysts' estimates. However, quarterly sales edged down and missed expectations. The company also reaffirmed its guidance range for the full-year 2022. While reporting financial results for the second quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided financial outlook for the third and the fourth quarters as well as slashed its guidance for the full-year 2023. For the third quarter, the company projects earnings in a range... American Airlines announced an agreement to purchase up to 20 Overture supersonic jets, the world's fastest airliner, from transportation start-up Boom Supersonic, with an option for an additional 40. Overture, which is expected to carry passengers at twice the speed of the fastest commercial aircraft available at present, would provide an important new speed advantage to American's fleet.